Julie Desrivot

1.0k total citations
22 papers, 826 citations indexed

About

Julie Desrivot is a scholar working on Molecular Biology, Public Health, Environmental and Occupational Health and Organic Chemistry. According to data from OpenAlex, Julie Desrivot has authored 22 papers receiving a total of 826 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Public Health, Environmental and Occupational Health and 5 papers in Organic Chemistry. Recurrent topics in Julie Desrivot's work include Research on Leishmaniasis Studies (6 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Julie Desrivot is often cited by papers focused on Research on Leishmaniasis Studies (6 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (4 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Julie Desrivot collaborates with scholars based in France, Belgium and Sweden. Julie Desrivot's co-authors include Reynald Hocquemiller, Christian Bories, Bruno Figadère, Philippe M. Loiseau, Alain Fournet, Xavier Franck, Sonia Dupont, Hui Xu, Ann Fieuw and Ellen M. van der Aar and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of Ethnopharmacology and Clinical Pharmacokinetics.

In The Last Decade

Julie Desrivot

22 papers receiving 793 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julie Desrivot France 12 304 214 154 152 116 22 826
Clarissa Araújo Gurgel Rocha Brazil 22 152 0.5× 491 2.3× 93 0.6× 16 0.1× 47 0.4× 72 1.1k
Biswajit Pal India 15 64 0.2× 358 1.7× 54 0.4× 86 0.6× 58 0.5× 36 627
Martin Hibbs United Kingdom 15 247 0.8× 419 2.0× 38 0.2× 29 0.2× 41 0.4× 25 1.0k
Fangyi Zhu United States 19 317 1.0× 436 2.0× 37 0.2× 186 1.2× 114 1.0× 42 1.0k
Victoria Palau United States 14 73 0.2× 459 2.1× 65 0.4× 51 0.3× 33 0.3× 30 860
Yan Cui China 12 101 0.3× 346 1.6× 49 0.3× 31 0.2× 76 0.7× 43 706
Raffaele Frazzi Italy 17 50 0.2× 454 2.1× 82 0.5× 31 0.2× 164 1.4× 39 937
Vidya P. Kumar United States 17 49 0.2× 269 1.3× 64 0.4× 30 0.2× 48 0.4× 47 571
Akhmed Aslam Saudi Arabia 18 83 0.3× 540 2.5× 39 0.3× 27 0.2× 44 0.4× 38 916
Hong Yi China 20 131 0.4× 489 2.3× 140 0.9× 8 0.1× 104 0.9× 63 893

Countries citing papers authored by Julie Desrivot

Since Specialization
Citations

This map shows the geographic impact of Julie Desrivot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Desrivot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Desrivot more than expected).

Fields of papers citing papers by Julie Desrivot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Desrivot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Desrivot. The network helps show where Julie Desrivot may publish in the future.

Co-authorship network of co-authors of Julie Desrivot

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Desrivot. A scholar is included among the top collaborators of Julie Desrivot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Desrivot. Julie Desrivot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Desrivot, Julie, et al.. (2021). Effect of GLPG1205, a GPR84 Modulator, on CYP2C9, CYP2C19, and CYP1A2 Enzymes: In Vitro and Phase 1 Studies. Clinical Pharmacology in Drug Development. 10(9). 1007–1017. 7 indexed citations
2.
Taneja, Amit, Julie Desrivot, Paul M. Diderichsen, et al.. (2019). Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis. Clinical Pharmacokinetics. 58(9). 1175–1191. 10 indexed citations
3.
Aar, Ellen van der, Julie Desrivot, Sonia Dupont, et al.. (2019). Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials. The Journal of Clinical Pharmacology. 59(10). 1366–1378. 34 indexed citations
4.
Aar, Ellen M. van der, Julie Desrivot, David Amantini, et al.. (2018). ADAMTS-5 inhibitor GLPG1972, a potential new treatment in osteoarthritis, shows favorable safety, pharmacokinetics and pharmacodynamics in healthy subjects. Osteoarthritis and Cartilage. 26. S310–S310. 9 indexed citations
5.
Maher, Toby M., Ellen M. van der Aar, Julie Desrivot, et al.. (2018). Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. The Lancet Respiratory Medicine. 6(8). 627–635. 175 indexed citations
6.
Vermeire, Séverine, et al.. (2017). P610 Efficacy and safety of GLPG1205, a GPR84 antagonist, in ulcerative colitis: multi-centre proof-of-concept study. Journal of Crohn s and Colitis. 11(suppl_1). S390–S391. 14 indexed citations
7.
Namour, Florence, et al.. (2016). Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions. Drug Metabolism Letters. 10(1). 38–48. 52 indexed citations
8.
Aar, Ellen van der, Julie Desrivot, Sonia Dupont, et al.. (2015). Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD. OA484–OA484. 6 indexed citations
9.
Namour, Florence, et al.. (2014). AB0460 Glpg0634, A Selective JAK1 Inhibitor, Confirms Its Low Liability for Drug-Drug Interactions. Annals of the Rheumatic Diseases. 73. 960–960. 1 indexed citations
10.
Aulner, Nathalie, Anne Danckaert, Julie Desrivot, et al.. (2013). High Content Analysis of Primary Macrophages Hosting Proliferating Leishmania Amastigotes: Application to Anti-leishmanial Drug Discovery. PLoS neglected tropical diseases. 7(4). e2154–e2154. 55 indexed citations
11.
Hamon, Véronique, Dragos Horvath, Cédric Gaudin, et al.. (2012). QSAR Modelling of CYP3A4 Inhibition as a Screening Tool in the Context of DrugDrug Interaction Studies. Molecular Informatics. 31(9). 669–677. 4 indexed citations
12.
Desrivot, Julie, et al.. (2008). Synthesis and biological evaluation of a series of tangeretin-derived chalcones. Bioorganic & Medicinal Chemistry Letters. 19(1). 167–169. 51 indexed citations
13.
Desrivot, Julie, Per‐Olof Edlund, Paweł Baranczewski, et al.. (2007). Metabolism of 2-substituted quinolines with antileishmanial activity studied in vitro with liver microsomes, hepatocytes and recombinantly expressed enzymes analyzed by LC/MS. Toxicology. 235(1-2). 27–38. 11 indexed citations
14.
Desrivot, Julie, Jean Waikedre, Pierre Cabalion, et al.. (2007). Antiparasitic activity of some New Caledonian medicinal plants. Journal of Ethnopharmacology. 112(1). 7–12. 62 indexed citations
15.
Nakayama, Héctor, Julie Desrivot, Christian Bories, et al.. (2007). In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani. Biomedicine & Pharmacotherapy. 61(2-3). 186–188. 33 indexed citations
16.
Desrivot, Julie, Fathi Moussa, Pierre Champy, et al.. (2007). Development of a SPE/HPLC/DAD method for the determination of antileishmanial 2-substituted quinolines and metabolites in rat plasma. Journal of Chromatography B. 854(1-2). 230–238. 5 indexed citations
17.
Desrivot, Julie, Christine Herrenknecht, Gilles Ponchel, et al.. (2007). Antileishmanial 2-substituted quinolines: In vitro behaviour towards biological components. Biomedicine & Pharmacotherapy. 61(7). 441–450. 21 indexed citations
18.
Xu, Hui, Julie Desrivot, Christian Bories, et al.. (2005). Synthesis and antiprotozoal activity of some new synthetic substituted quinoxalines. Bioorganic & Medicinal Chemistry Letters. 16(4). 815–820. 171 indexed citations
19.
Mesquita, Mariana Laundry de, Julie Desrivot, Alain Fournet, et al.. (2005). Antileishmanial and trypanocidal activity of Brazilian Cerrado plants. Memórias do Instituto Oswaldo Cruz. 100(7). 783–787. 96 indexed citations
20.
Seck, Matar, Julie Desrivot, Christian Bories, et al.. (2005). [Antileishmanial activity of five 2- or 3- quinolines by enyne group].. PubMed. 50(1). 1–4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Clarissa Araújo Gurgel Rocha Breakdown of academic impact, for papers by Biswajit Pal Breakdown of academic impact, for papers by Martin Hibbs Breakdown of academic impact, for papers by Fangyi Zhu Breakdown of academic impact, for papers by Victoria Palau Breakdown of academic impact, for papers by Yan Cui Breakdown of academic impact, for papers by Raffaele Frazzi Breakdown of academic impact, for papers by Vidya P. Kumar Breakdown of academic impact, for papers by Akhmed Aslam Breakdown of academic impact, for papers by Hong Yi
Rankless by CCL
2026